›4.5 g IV every 6 hours
›Covers gram-negative, gram-positive, and anaerobic organisms
›Ceftriaxone plus metronidazole alternative
›Ceftriaxone 2 g IV every 24 hours
›Metronidazole 500 mg IV every 8 hours
›Meropenem for resistant organism risk or prior colonization
›1 g IV every 8 hours
›Reserve for high-resistance risk environments
›Add vancomycin if MRSA risk or healthcare-associated infection
›15 to 20 mg/kg IV every 8 to 12 hours
›AUC-guided dosing per local protocol
›Antibiotic timing
›Within 1 hour of diagnosis for septic shock
›Class I recommendation per Surviving Sepsis Campaign
›Do not delay for blood cultures if patient unstable
›Segmental resection is the gold standard and preferred treatment
›Ileocecectomy or right hemicolectomy
›ASCRS clinical practice guidelines recommend resection
›Zero recurrence rate with resection
›Preferred over nonresective options for all appropriate surgical candidates
›Primary ileocolic anastomosis when safe
›Anastomotic leak rate approximately 4.1% in NSQIP data
›Mortality approximately 3.3% in NSQIP data for uncomplicated cases
›Resection with end ileostomy and mucous fistula
›High-risk patients with nonviable bowel
›Septic shock state with bowel contamination
›Second-stage anastomosis possible after recovery
›Nonresective options for patients unfit for resection
›Cecopexy
›Surgical fixation of cecum without resection
›Recurrence rate 13%; lower morbidity 15% and mortality 10%
›Reserved for viable bowel and very high surgical risk patients only
›Cecostomy
›Highest complication rates: morbidity 52%, mortality 32%
›Generally discouraged by ASCRS guidelines
›Considered only when resection and cecopexy not feasible
›Detorsion alone without fixation
›Recurrence rate up to 75%
›Not recommended as definitive treatment
›Endoscopic reduction is not recommended
›Success rate only 14% for cecal volvulus
›Significantly lower than sigmoid volvulus endoscopic success
›ASGE and ASCRS guidelines advise against endoscopy for cecal volvulus
›Risk of perforation and delay to definitive surgical care
›Failed endoscopy worsens operative risk
›Proceed directly to operative management
Laparoscopic versus open surgery
›Approach selection
›Laparoscopic approach feasible in stable patients with viable bowel
›Conversion to open if difficult exposure or necrosis found
›Similar outcomes to open in experienced centers
›Open laparotomy for unstable, peritonitis, or perforation
›Faster access in emergent cases
›Better visualization for contaminated fields
›Surgical approach guided by individual patient and operative team factors
›Center experience and available equipment
›Degree of cecal distension affecting laparoscopic feasibility
›Deep vein thrombosis prophylaxis
›Sequential compression devices preoperatively
›Low molecular weight heparin postoperatively when hemostasis secured
›Enoxaparin 40 mg subcutaneous once daily
›Colorectal surgery carries high VTE risk without prophylaxis
›Glycemic control perioperatively
›Target blood glucose 6 to 10 mmol/l
›Insulin infusion for persistent hyperglycemia
›Hypoglycemia avoidance
›Thromboprophylaxis and anticoagulation reversal
›Reversal of anticoagulation if emergent surgery required
›Vitamin K and fresh frozen plasma for warfarin
›Idarucizumab for dabigatran
›Andexanet alfa for factor Xa inhibitors if available